182 related articles for article (PubMed ID: 21876633)
1. Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma.
Shu Y; Wang B; Wang J; Wang JM; Zou SQ
World J Gastroenterol; 2011 Aug; 17(29):3407-19. PubMed ID: 21876633
[TBL] [Abstract][Full Text] [Related]
2. Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors.
Sriraksa R; Zeller C; Dai W; Siddiq A; Walley AJ; Limpaiboon T; Brown R
Cancer Prev Res (Phila); 2013 Dec; 6(12):1348-55. PubMed ID: 24089088
[TBL] [Abstract][Full Text] [Related]
3. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.
Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D
Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma.
Yang B; House MG; Guo M; Herman JG; Clark DP
Mod Pathol; 2005 Mar; 18(3):412-20. PubMed ID: 15467712
[TBL] [Abstract][Full Text] [Related]
5. Aberrant DNA methylation of integrin alpha4: a potential novel role for metastasis of cholangiocarcinoma.
Uhm KO; Lee JO; Lee YM; Lee ES; Kim HS; Park SH
J Cancer Res Clin Oncol; 2010 Feb; 136(2):187-94. PubMed ID: 19655168
[TBL] [Abstract][Full Text] [Related]
6. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma.
Uhm KO; Lee ES; Lee YM; Kim HS; Park YN; Park SH
Oncol Res; 2008; 17(4):151-7. PubMed ID: 18773859
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a CpG island methylator phenotype-related prognostic signature for cholangiocarcinoma.
Liang J; Liu T; Liao J; Zhang L; Zhou M; Xu W; He Y; Cai G; Jin G; Song J; Li G; Liang H; Ding Z; Zhang B
J Cell Physiol; 2021 Apr; 236(4):3143-3156. PubMed ID: 32996133
[TBL] [Abstract][Full Text] [Related]
9. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma.
Andresen K; Boberg KM; Vedeld HM; Honne H; Hektoen M; Wadsworth CA; Clausen OP; Karlsen TH; Foss A; Mathisen O; Schrumpf E; Lothe RA; Lind GE
Epigenetics; 2012 Nov; 7(11):1249-57. PubMed ID: 22983262
[TBL] [Abstract][Full Text] [Related]
10. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.
Kim BH; Cho NY; Choi M; Lee S; Jang JJ; Kang GH
Arch Pathol Lab Med; 2007 Jun; 131(6):923-30. PubMed ID: 17550320
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma.
Nanok C; Jearanaikoon P; Proungvitaya S; Limpaiboon T
Mol Med Rep; 2018 Mar; 17(3):4145-4153. PubMed ID: 29359783
[TBL] [Abstract][Full Text] [Related]
12. MiR-376c down-regulation accelerates EGF-dependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line.
Iwaki J; Kikuchi K; Mizuguchi Y; Kawahigashi Y; Yoshida H; Uchida E; Takizawa T
PLoS One; 2013; 8(7):e69496. PubMed ID: 23922722
[TBL] [Abstract][Full Text] [Related]
13. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma.
Chen YJ; Tang QB; Zou SQ
World J Gastroenterol; 2005 Mar; 11(9):1333-8. PubMed ID: 15761971
[TBL] [Abstract][Full Text] [Related]
15. Screening of potential biomarkers for cholangiocarcinoma by integrated analysis of microarray data sets.
Huang QX; Cui JY; Ma H; Jia XM; Huang FL; Jiang LX
Cancer Gene Ther; 2016; 23(2-3):48-53. PubMed ID: 26679756
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.
Wehbe H; Henson R; Meng F; Mize-Berge J; Patel T
Cancer Res; 2006 Nov; 66(21):10517-24. PubMed ID: 17079474
[TBL] [Abstract][Full Text] [Related]
17. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
Likhitrattanapisal S; Tipanee J; Janvilisri T
Tumour Biol; 2016 Sep; 37(9):12755-12766. PubMed ID: 27448818
[TBL] [Abstract][Full Text] [Related]
19. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
20. Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma.
Chen YJ; Luo J; Yang GY; Yang K; Wen SQ; Zou SQ
World J Gastroenterol; 2012 Aug; 18(29):3849-61. PubMed ID: 22876037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
